These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24615122)

  • 21. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation.
    Moorthy V; Reed Z; Smith PG;
    Vaccine; 2007 Jul; 25(28):5115-23. PubMed ID: 17577487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Some statistical issues in HIV vaccine trials.
    Rida WN; Lawrence DN
    Stat Med; 1994 Oct 15-30; 13(19-20):2155-77. PubMed ID: 7846417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies.
    Chin'ombe N; Ruhanya V
    Pan Afr Med J; 2015; 20():386. PubMed ID: 26185576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A live-virus "suicide" vaccine for human immunodeficiency virus.
    Kestler HW; Chakrabarti BK
    Cleve Clin J Med; 1997 May; 64(5):269-74. PubMed ID: 9149478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gender aspects on HIV prevention efforts and participation in HIV vaccine trials among Police officers in Dar es Salaam, Tanzania.
    Tarimo EAM; Kakoko DCV; Kohi TW; Bakari M; Sandstrom E; Siyame D; Mhalu F; Kulane A
    BMC Public Health; 2018 Jul; 18(1):905. PubMed ID: 30031376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The Global Fund to fight HIV/AIDS, TB and Malaria 5-y: evaluation policy issues].
    Kerouedan D
    Bull Soc Pathol Exot; 2010 May; 103(2):119-22. PubMed ID: 20376595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing country trialists are key for malaria vaccine goals.
    Lancet; 2006 Dec; 368(9554):2185. PubMed ID: 17189009
    [No Abstract]   [Full Text] [Related]  

  • 28. A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants.
    Afolabi MO; Ndure J; Drammeh A; Darboe F; Mehedi SR; Rowland-Jones SL; Borthwick N; Black A; Ambler G; John-Stewart GC; Reilly M; Hanke T; Flanagan KL
    PLoS One; 2013; 8(10):e78289. PubMed ID: 24205185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Designing an effective AIDS vaccine: strategies and current status].
    Coutsinos Z; Absi Z; Henin Y; Guillet JG; Launay O
    Rev Med Interne; 2008 Aug; 29(8):632-41. PubMed ID: 18258341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Country planning for health interventions under development: lessons from the malaria vaccine decision-making framework and implications for other new interventions.
    Brooks A; Ba-Nguz A
    Health Policy Plan; 2012 May; 27 Suppl 2(Suppl 2):ii50-61. PubMed ID: 22513733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An HIV vaccine: how and when?
    Esparza J
    Bull World Health Organ; 2001; 79(12):1133-7. PubMed ID: 11799445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines.
    Fowkes FJ; Simpson JA; Beeson JG
    BMC Med; 2013 Oct; 11():232. PubMed ID: 24228861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scientific and social issues of human immunodeficiency virus vaccine development.
    Haynes BF
    Science; 1993 May; 260(5112):1279-86. PubMed ID: 8493572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trial objectives and end points for measuring the efficacy of HIV vaccines.
    Hoff R; Barker LF
    Infect Agents Dis; 1995 Jun; 4(2):95-101. PubMed ID: 7613732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Commodifying Vaccines to Curtail Antibiotic Resistance Impact in Malaria Endemic Countries.
    Khan M
    J Coll Physicians Surg Pak; 2023 Dec; 33(12):1454-1456. PubMed ID: 38062606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The WHO statement on strategies of HIV vaccinations: field trials in developing countries should await studies of the effects].
    Lennholm B
    Lakartidningen; 1993 Mar; 90(13):1245-6. PubMed ID: 8469070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome research.
    Fischer E; Rieux V; Guillet JG; Kazatchkine M
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):79-84. PubMed ID: 15867969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances and challenges in malaria vaccine development.
    Wang R; Smith JD; Kappe SH
    Expert Rev Mol Med; 2009 Dec; 11():e39. PubMed ID: 20003658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Present situation regarding development of an HIV vaccine].
    Alcami J
    Enferm Infecc Microbiol Clin; 2002 Dec; 20(10):511-22. PubMed ID: 12433353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interpreting challenge data from early phase malaria blood stage vaccine trials.
    Good MF; Miller LH
    Expert Rev Vaccines; 2018 Mar; 17(3):189-196. PubMed ID: 29382292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.